证券代码：301301 证券简称：川宁生物 伊犁川宁生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|-----------------|-----------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | 活动类别 | | | | | □现场参观 | | | | □其他：电话调研 | | | 参与单位名称 | | | | 及人员姓名 | （网址： | https://eseb.cn/14yPfeAv1hm | 时间 2023 年 5 月 15 日 16:00-17:00 地点 价值在线（https://www.ir-online.cn/）网络互动 董事、总经理邓旭衡先生；董事、副总经理、财务总监李懿 上市公司接待 行先生；副总经理、董事会秘书顾祥先生；副总经理、销售 总监姜海先生；副总经理、首席科学家赵华先生；独立董事 人员姓名 段宏女士；长江证券保荐代表人李忠先生。 1.恭喜公司 22 年营收、净利润双增长， ...

证券代码：301301 证券简称：川宁生物 公告编号：2023-041 伊犁川宁生物技术股份有限公司 关于举办2022年度业绩说明会的公告 重要内容提示： 会议召开时间：2023 年 05 月 15 日（星期一）16:00-17:00 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 会议问题征集： 投 资 者 可 于 2023 年 05 月 15 日 前 访问网址 https://eseb.cn/14yPfeAv1hm或使用微信扫描下方小程序码进行会前提问，公 司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题 进行回答。 会议召开方式：网络互动方式 二、出席嘉宾 伊犁川宁生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 4 日在巨潮资讯网上披露了《伊犁川宁生物技术股份有限公司 2022 年年度报告》 及《伊犁川宁生物技术股份有限公司 2022 年年度报告摘要》。为便于广大投资 者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 05 月 15 日（星期一）16:00-17:00 在"价值在线"（www. ...

Group 1: Company Overview and Performance - The management provided a brief introduction to the company's operations and Q1 performance [3] - The company has developed two agents for its first synthetic biology product, with a sales expectation of 10 tons [3] - The company anticipates a stable increase in the price trend of antibiotic products in 2023 [4] Group 2: Product Development and Market Strategy - The market demand for the product "Red Yeast" is estimated between 500-800 tons, with the main competitor being BASF [4] - The company plans to produce 300 tons of "Red Yeast" annually, with no immediate expansion plans due to current global market demand [5] - The company aims for over 30% gross margin on mature products and over 50% on high-value products [7] Group 3: Financial Management and Cost Control - The company has invested over 2 billion in environmental protection, with limited room for cost reduction in operational expenses [5] - Management expenses have decreased year-on-year due to accounting adjustments [5] - The company has a credit policy for customer payments set at 2-3 months [7] Group 4: Future Outlook and Market Trends - The company expects stable demand for its main products throughout the year, with confidence in achieving profit targets set in the equity incentive plan [5] - The current market price for "Red Yeast" is between 800-1200 RMB/kg, and for 5-Hydroxytryptophan, it is between 800-1000 RMB/kg [7]

Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,269,733,317.68, representing a 27.34% increase compared to ¥997,089,543.13 in the same period last year[5] - Net profit attributable to shareholders was ¥174,273,801.35, marking a 74.56% increase from ¥99,834,595.77 year-on-year[5] - Basic and diluted earnings per share increased by 60.00%, from ¥0.05 to ¥0.08[5] - The total operating revenue for Q1 2023 was CNY 1,269,733,317.68, representing an increase of 27.3% compared to CNY 997,089,543.13 in the same period last year[17] - The net profit attributable to the parent company was CNY 175,446,682.72, up 74.4% from CNY 100,595,613.95 in Q1 2022[19] - The total operating costs for Q1 2023 were CNY 1,040,861,350.07, an increase of 18.6% from CNY 876,873,257.88 in the previous year[18] - Research and development expenses amounted to CNY 13,774,801.25, which is a 29.8% increase compared to CNY 10,648,788.15 in Q1 2022[18] - The earnings per share (EPS) for Q1 2023 was CNY 0.08, compared to CNY 0.05 in the same period last year, marking a 60% increase[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥45,161,408.27, a significant decline of 1,587.75% compared to ¥3,035,553.68 in the previous year[11] - The cash flow from operating activities was CNY 497,255,911.49, a decrease from CNY 552,370,253.53 in the same quarter last year[19] - The total cash outflow from operating activities was CNY 569,522,656.06, an increase of 3.6% from CNY 550,549,856.01 in the previous period[21] - The net cash flow from investing activities was -CNY 4,830,726.92, an improvement from -CNY 10,104,116.74 in the previous period[21] - Cash inflow from financing activities was CNY 1,800,000.00, significantly lower than CNY 286,375,700.00 in the previous period[21] - The total cash outflow from financing activities was CNY 552,167,881.27, an increase from CNY 296,878,751.26 in the previous period[21] - The net cash flow from financing activities was -CNY 550,367,881.27, worsening from -CNY 10,503,051.26 in the previous period[21] - The cash and cash equivalents at the end of the period were CNY 1,023,534,016.97, compared to CNY 489,738,911.25 at the end of the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,114,160,972.62, a decrease of 2.66% from ¥10,390,399,359.24 at the end of the previous year[5] - Accounts receivable increased to ¥1,021,309,437.18 from ¥877,597,384.20, reflecting a growth of about 16.3%[15] - Inventory decreased to ¥1,066,692,446.32 from ¥1,383,634,677.19, indicating a reduction of approximately 23.0%[15] - Current liabilities total ¥2,451,994,634.16, down from ¥2,707,385,477.45, a decrease of approximately 9.4%[16] - Long-term borrowings decreased to ¥1,022,999,996.00 from ¥1,428,000,000.00, a reduction of about 28.4%[16] - The total liabilities decreased to CNY 3,728,227,308.83 from CNY 4,179,912,376.97 at the beginning of the year, reflecting a reduction of 10.7%[17] - The deferred income decreased slightly to CNY 33,177,830.24 from CNY 34,240,935.05 at the beginning of the year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 59,854[12] - Sichuan Kelun Pharmaceutical holds 70.63% of shares, totaling 1,569,887,643 shares[12] - The total equity attributable to shareholders of the parent company increased to CNY 6,379,931,942.92 from CNY 6,204,485,260.20 at the beginning of the year, reflecting a growth of 2.8%[17] Expenses and Taxation - Management expenses decreased by 47.51% to ¥41,062,024.57 from ¥78,226,671.83 in the same period last year[10] - The company experienced a 90.66% increase in income tax expenses, rising to ¥34,938,429.41 from ¥18,324,953.79[10] - The financial expenses for the quarter were CNY 23,979,158.76, down from CNY 37,145,447.06 in the previous year, indicating a reduction of 35.5%[18] - Tax payments increased to CNY 127,956,669.11 from CNY 35,835,646.80 in the previous period, indicating a substantial rise in tax obligations[20] Other Information - The company plans to expand its agricultural land leasing business, which contributed to the increase in right-of-use assets[9] - The company received government subsidies amounting to ¥2,235,251.24, an increase of 74.45% compared to ¥1,281,281.80 in the previous year[10] - The company reported a significant increase in employee compensation payments, totaling CNY 119,280,108.62, up from CNY 98,469,929.66 in the previous period[20] - The company did not conduct an audit for the first quarter report[21] - The company has a goodwill value of ¥1,365,974.00, unchanged from the previous period[16]

Financial Performance - The company's operating revenue for 2022 was ¥3,820,657,857.71, an increase of 18.21% compared to ¥3,232,014,638.04 in 2021[11]. - The net profit attributable to shareholders for 2022 was ¥411,518,024.65, representing a significant increase of 269.58% from ¥111,346,659.27 in 2021[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥446,630,289.76, up 147.15% from ¥180,710,589.01 in 2021[11]. - The company's cash flow from operating activities for 2022 was ¥691,638,049.25, a decrease of 13.89% compared to ¥803,211,175.51 in 2021[11]. - The basic earnings per share for 2022 was ¥0.21, a 250.00% increase from ¥0.06 in 2021[11]. - The total assets at the end of 2022 were ¥10,390,399,359.24, reflecting a growth of 9.82% from ¥9,461,536,586.60 at the end of 2021[11]. - The net assets attributable to shareholders at the end of 2022 were ¥6,204,485,260.20, an increase of 30.04% from ¥4,771,284,144.72 at the end of 2021[11]. - The company achieved a total revenue of 606.76 million CNY for the reporting period[147]. - The total operating income of the evaluated units accounted for 97.74% of the company's consolidated financial statement operating income[165]. Dividend Policy - The company plans to distribute a cash dividend of 0.93 CNY per 10 shares to all shareholders, based on a total of 222,280,000 shares[2]. - The net profit attributable to shareholders reached RMB 412 million, a significant increase of 269.58% compared to the previous year[55]. - The company achieved a net profit attributable to shareholders of 411,518,024.65 CNY for the year 2022, with a profit distribution plan proposing a cash dividend of 0.93 CNY per 10 shares, totaling 206,720,400.00 CNY, which represents 50.23% of the net profit[161]. - The total distributable profit at the end of 2022 was 666,044,232.52 CNY, with retained earnings of 459,323,832.52 CNY to be carried forward for future distribution[161]. - The company has committed to a three-year dividend return plan to actively reward investors and protect the rights of minority shareholders[158]. Research and Development - The company reported a significant focus on research and development, with potential risks including industry policy changes and market risks[2]. - The company has established a comprehensive synthetic biology platform that includes a computational biology strain design platform and an automated high-throughput strain construction and screening platform, significantly improving R&D efficiency[31]. - The total R&D investment for 2022 was ¥35,381,740.73, accounting for 0.93% of operating revenue, a decrease from 1.41% in 2021[77]. - Research and development expenses increased by 7.37% to ¥35,381,740.73, indicating ongoing investment in innovation[72]. - The number of R&D personnel increased to 132 in 2022, representing a growth of 6.45% compared to 124 in 2021[76]. - The company is advancing several R&D projects aimed at enhancing product lines and market competitiveness, including the development of 7-ADCA through biotechnological methods[73]. Market Position and Strategy - The company holds a 43.86% market share in the thiocyanate erythromycin market, with an annual production capacity of approximately 3,000 tons, ranking second in the industry[25]. - In the cephalosporin intermediate market, the company has a total production capacity of about 3,000 tons per year, with a market share of 37.00%, making it the industry leader[25]. - The company's penicillin intermediate production capacity is approximately 6,700 tons per year, holding an 18.00% market share, ranking second in the industry[25]. - The company is positioned as a leading enterprise in the antibiotic intermediate market, benefiting from a robust industrial production system[25]. - The company aims to transition from resource-driven to technology-driven growth, enhancing its operational efficiency and market competitiveness[33]. Governance and Compliance - The company has established a strong governance structure with a board of directors and supervisory board ensuring accountability[3]. - The board of directors consists of 7 members, including 3 independent directors, and held 6 meetings during the reporting period[113]. - The company has established several engineering technology centers and has been recognized as a model for green manufacturing and intelligent manufacturing[39]. - The company has a clear and complete asset ownership structure, with no reliance on the controlling shareholder or related entities[123]. - The company has established an independent financial department and maintains a separate bank account, ensuring no shared accounts with the controlling shareholder[126]. Environmental Responsibility - The company has invested nearly 2.5 billion yuan in environmental protection facilities, accounting for over 25% of total project investment[49]. - The company has developed a project for the regeneration of saturated granular activated carbon, utilizing clean fuel biogas from its wastewater treatment system[176]. - The company has established multiple environmental management systems to ensure effective waste treatment and compliance with environmental standards[169]. - The company is actively responding to national carbon peak and carbon neutrality goals, establishing a greenhouse gas emission management system[176]. - The company has implemented strict environmental standards and continuously increases investment in environmental protection[179]. Risk Management - The company has a comprehensive risk management strategy to address environmental, quality control, and innovation risks[2]. - The company aims to mitigate foreign exchange risks through hedging strategies, ensuring compliance with relevant regulations and internal controls[89]. - The risk control measures include avoiding speculative trading and focusing on hedging to protect against significant currency fluctuations[89]. - The company has established a management system for foreign exchange hedging, detailing operational procedures, approval authority, and risk reporting mechanisms[89]. Investment and Financing - The total amount of funds raised in the IPO was RMB 1,114 million, with a net amount of RMB 1,021 million after deducting expenses[90]. - The company has committed to invest RMB 60 million in projects, with RMB 40 million already utilized for repaying bank loans, achieving a 100% investment progress[92]. - The financing activities generated a net cash flow of ¥475,923,386.14, a significant increase of 163.52% compared to the previous year, primarily due to public share issuance[78]. Community Engagement - The company actively supports rural revitalization by purchasing local agricultural products, employing over 40 villagers from the Yingyeer Village[185]. - The company has participated in the "Hundred Enterprises Help Hundred Villages" initiative, focusing on practical assistance and job creation for local residents[185]. - The company has made significant contributions to poverty alleviation efforts in Xinjiang, enhancing social stability and economic development[185].